Compass Therapeutics, Inc.
CMPX
$5.30
-$0.02-0.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 44.37% | -35.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.74% | -24.92% | |||
| Operating Income | -13.74% | 24.92% | |||
| Income Before Tax | -10.22% | 28.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.22% | 28.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.22% | 28.28% | |||
| EBIT | -13.74% | 24.92% | |||
| EBITDA | -13.77% | 24.65% | |||
| EPS Basic | -0.59% | 41.24% | |||
| Normalized Basic EPS | -0.57% | 41.27% | |||
| EPS Diluted | -0.59% | 41.24% | |||
| Normalized Diluted EPS | -0.57% | 41.27% | |||
| Average Basic Shares Outstanding | 9.52% | 22.06% | |||
| Average Diluted Shares Outstanding | 9.52% | 22.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||